Q1 Earnings Estimate for ELDN Issued By Noble Financial

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Investment analysts at Noble Financial issued their Q1 2026 earnings estimates for shares of Eledon Pharmaceuticals in a research report issued on Monday, March 23rd. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.08) for the quarter. The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share. Noble Financial also issued estimates for Eledon Pharmaceuticals’ Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.91) EPS.

Eledon Pharmaceuticals (NASDAQ:ELDN) last released its earnings results on Thursday, March 19th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.10.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Eledon Pharmaceuticals in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Eledon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $9.67.

Eledon Pharmaceuticals Stock Performance

Shares of NASDAQ:ELDN opened at $2.89 on Wednesday. The stock’s 50-day moving average is $2.39 and its 200-day moving average is $2.35. The company has a market cap of $219.21 million, a P/E ratio of -5.56 and a beta of 0.84. Eledon Pharmaceuticals has a 52-week low of $1.35 and a 52-week high of $4.60.

Hedge Funds Weigh In On Eledon Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets lifted its position in shares of Eledon Pharmaceuticals by 143.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,154 shares of the company’s stock worth $31,000 after acquiring an additional 7,166 shares during the period. ProShare Advisors LLC acquired a new position in shares of Eledon Pharmaceuticals in the second quarter valued at $33,000. Millennium Management LLC bought a new position in Eledon Pharmaceuticals in the fourth quarter worth $36,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Eledon Pharmaceuticals in the 2nd quarter valued at $37,000. Finally, Virtu Financial LLC bought a new stake in Eledon Pharmaceuticals in the 4th quarter valued at $39,000. Institutional investors and hedge funds own 56.77% of the company’s stock.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications.